[Fundamental and clinical evaluation on ceftriaxone in the pediatric field]. 1984

Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori

Fundamental and clinical evaluation on ceftriaxone (Ro 13-9904, CTRX) was performed. CTRX was compared with CEZ, CMZ, CTX and LMOX in the antibacterial activity against the clinical isolates such as S. aureus, E. coli, P. mirabilis, K. pneumoniae and S. marcescens. Against S. aureus, the MIC of CTRX ranged from 0.2 to greater than 100 micrograms/ml with a peak of 3.13 micrograms/ml, showing that CTRX was almost equal to CTX in activity, slightly superior to LMOX and much inferior to CMZ and CEZ, although some strains were not susceptible to CEZ. Against the intestinal strains of E. coli, K. pneumoniae and P. mirabilis, the MIC distribution of CTRX was similar to that of CTX and LMOX while CTRX showed the MIC as high as 3.13 micrograms/ml or above against 44% of all strains including the beta-lactamase producing strains of E. coli and K. pneumoniae, indicating a slight tendency of their becoming resistant. The MIC peaks against E. coli, K. pneumoniae and P. mirabilis were less than or equal to 0.1, 0.39 and less than or equal to 0.1 microgram/ml, respectively. As to S. marcescens which is drawing attention as a causative agent for infections inside of hospitals or those among young infants, CTRX inhibited 84% of the strains at 3.13 micrograms/ml, showing a definite superiority to CEZ and CMZ and a slight superiority to CTX and LMOX. The serum concentration after a single intravenous injection with 40 mg/kg reached a mean peak of 168.8 micrograms/ml at the first blood sampling (at 30 minutes) and gradually decreased to 137.5 micrograms/ml at 1 hour, 30.9 micrograms/ml at 6 hours, 12.6 micrograms/ml at 12 hours and 3.8 micrograms/ml at 24 hours, while the half-life time was 6.0 hours. The comparison of the serum level by 1 hour intravenous drip infusion between the dosage groups of 20 mg/kg and 40 mg/kg revealed that the former group reached a peak of 85.4 micrograms/ml at the termination of drip while the latter's peak was 176.6 micrograms/ml observed during the drip (30 minutes after the initiation of drip). The respective levels of the 2 groups were 15.4 and 32.1 micrograms/ml at 6 hours, 5.1 and 15.0 micrograms/ml at 12 hours, and 1.6 and 4.1 micrograms/ml at 24 hours, indicating a distinct dose-response 2 hours after the initiation of drip administration. The half-life times were 4.9 and 6.2 hours, respectively, which are the longest among the cephalosporins presently being developed.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
November 1984, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
November 1984, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
November 1984, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
November 1984, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
December 1984, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
November 1984, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
November 1984, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
December 1984, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
December 1984, The Japanese journal of antibiotics,
Y Toyonaga, and Y Kurosu, and T Uekusa, and H Nakamura, and M Sugita, and T Okabe, and K Kawamura, and K Seo, and T Takahashi, and M Hori
November 1984, The Japanese journal of antibiotics,
Copied contents to your clipboard!